IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

GlobeNewswire Inc. | Sep 24, 2026 8:05 AM EDT